Efgartigimod alfa (Vyvgart®). HTA ID: 23026

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23026
Drug Efgartigimod alfa
Brand Vyvgart®
Indication Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive.
Assessment Process
Rapid review commissioned 12/05/2023
Rapid review completed 19/06/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of efgartigimod alfa compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/06/2023
Pre-submission consultation with Applicant 07/11/2023